PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Clinical trials for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT explained in plain language.
Never miss a new study
Get alerted when new PROSTATIC NEOPLASMS, CASTRATION-RESISTANT trials appear
Sign up with your email to follow new studies for PROSTATIC NEOPLASMS, CASTRATION-RESISTANT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
AI could predict when prostate cancer becomes resistant to treatment
Diagnosis Not yet recruitingThis study tests an artificial intelligence (AI) model that uses images from prostate biopsies to predict when prostate cancer will become resistant to hormone therapy. Researchers will enroll 150 patients with intermediate- to high-risk prostate cancer who are starting hormone t…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Diagnosis
Last updated Jun 27, 2026 09:00 UTC
-
Massive data dive aims to uncover best prostate cancer treatments in real life
Knowledge-focused Not yet recruitingThis study looks at how men with advanced prostate cancer that no longer responds to hormone therapy are treated in real-world clinics across the United States. Researchers will analyze data from over 17,000 patients to see which therapies are used, in what order, and how long th…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Mapping the next steps: how men with advanced prostate cancer are treated after standard therapies fail
Knowledge-focused Not yet recruitingThis study looks at real-world data from over 1,000 men with metastatic castration-resistant prostate cancer (mCRPC) who have already received several standard treatments, including hormone therapy, chemotherapy, and a targeted radiation drug called Lu-177 PSMA-617. Researchers w…
Matched conditions: PROSTATIC NEOPLASMS, CASTRATION-RESISTANT
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC